The lung cancer breath signature: a comparative analysis of exhaled breath and air sampled from inside the lungs.

Results collected in more than 20 years of studies suggest a relationship between the volatile organic compounds exhaled in breath and lung cancer. However, the origin of these compounds is still not completely elucidated. In spite of the simplistic vision that cancerous tissues in lungs directly emit the volatile metabolites into the airways, some papers point out that metabolites are collected by the blood and then exchanged at the air-blood interface in the lung. To shed light on this subject we performed an experiment collecting both the breath and the air inside both the lungs with a modified bronchoscopic probe. The samples were measured with a gas chromatography-mass spectrometer (GC-MS) and an electronic nose. We found that the diagnostic capability of the electronic nose does not depend on the presence of cancer in the sampled lung, reaching in both cases an above 90% correct classification rate between cancer and non-cancer samples. On the other hand, multivariate analysis of GC-MS achieved a correct classification rate between the two lungs of only 76%. GC-MS analysis of breath and air sampled from the lungs demonstrates a substantial preservation of the VOCs pattern from inside the lung to the exhaled breath.

An investigation on electronic nose diagnosis of lung cancer.

The use of gas sensor arrays as medical diagnosis instruments has been proposed several years ago. Since then, the idea has been proven for a limited number of diseases. The case of lung cancer is particularly interesting because it is supported by studies that have shown the correlation between the composition of breath and the disease. However, it is known that many other diseases can alter the breath composition, so for lung cancer diagnosis it is necessary not only to detect generic alterations but those specifically consequent to cancer. In this paper an experiment, performed in the bronchoscopy unit of a large hospital, aimed at discriminating between lung cancer, diverse lung diseases and reference controls is illustrated. Results show not only a satisfactory identification rate of lung cancer subjects but also a non-negligible sensitivity to breath modification induced by other affections. Furthermore, the effects of some compounds frequently found in the breath of lung cancer subjects have also been studied. Results indicate that breath samples of control individuals drift towards the lung cancer group when added with either single or mixtures of these alleged cancer-related compounds.

Identification of schizophrenic patients by examination of body odor using gas chromatography-mass spectrometry and a cross-selective gas sensor array.

BACKGROUND: Previous findings have shown that the body odor of patients affected by schizophrenia contains some specific compounds. Chemical sensor technology has proved to be able to classify different odours. We investigated the possibility of using a chemical sensor array to detect body odor alteration in schizophrenic patients. MATERIAL/METHODS: The sweat of subjects was sampled and analysed by Gas Chromatography-Mass Spectrometry (GC-MS) and by an array of cross-selective gas sensors. A total of 27 individuals were involved in the experiment: 9 schizophrenics, 9 with other mental disorders, and 9 controls. RESULTS: GC-MS analysis showed a richer composition for the sweat of schizophrenic patients. Nevertheless, the individuation of specific markers was unsuccessful. On the other hand, statistical analysis of cross-selective gas sensor data provided a complete classification of schizophrenic patients with respect to the other three groups. CONCLUSIONS: The alteration of body odor in schizophrenic patients was confirmed by GC-MS and chemical sensor array. Results show that the alteration is complex and cannot be limited to a single compound, but rather to a global variation of the body odor.

Lung cancer identification by the analysis of breath by means of an array of non-selective gas sensors.

Previous finding shown that the composition of the breath of patients with lung cancer contains information that could be used to detect the disease. These volatiles are mainly alkanes and aromatic compounds. Sensor arrays technology (electronic nose) proved to be useful to screen samples characterised by different headspace composition. Here we investigated the possibility of using an electronic nose to check whether volatile compounds present in expired air may diagnose lung cancer. Breath samples were collected and immediately analysed by an electronic nose. A total of 60 individuals were involved in the experiment. 35 of them were affected by lung cancer, 18 individuals were measured as reference and nine were measured after the surgical therapy. Two individuals were measured twice, before and after the surgical therapy, for a total of 62 measurements. An electronic nose, composed by eight quartz microbalance (QMB) gas sensors, coated with different metalloporphyrins, was used. These sensors show a good sensitivity towards those compounds previously indicated as possible lung cancer markers in breath. The application of a 'partial least squares-discriminant analysis' (PLS-DA) found out a 100% of classification of lung cancer affected patients, 94% of reference was correctly classified. The class of post-surgery patients were correctly individuated in 44% of the cases, while the other samples were classified as healthy references. The alteration of breath composition induced by the presence of lung cancer was enough to allow a complete identification of the sample of diseased individuals. Extended studies are necessary to evaluate the resolution of the method, namely the stage at which the disease may be identified in order to use this instrument for early diagnosis.